<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.17.9.post6+86293ac&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;fc=20 230708114047&amp;ff=20230829060820&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U- NVu8003KrCpq8yLQC -<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.17.9.post6+86293ac&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;fc=20230708114047&amp;ff=20230829060820&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 8 月 29 日星期二 10:08:22 +0000</lastbuilddate><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>降脂治疗后冠状动脉粥样硬化的消退和稳定</title><link/>https://pubmed.ncbi.nlm.nih.gov/37640248/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829060820&amp;v=2.17.9.post6+86293ac<description>结论：三分之一接受高强度降脂治疗的 AMI 患者出现三重回归，并且与 alirocumab 治疗、较高的基线脂质含量和减少的心血管事件相关。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 20 日：S0735-1097(23)06468-9。doi：10.1016/j.jacc.2023.08.019。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：接受高强度降脂治疗并同时出现粥样斑块体积减少、脂质含量减少和纤维帽厚度增加（即“三重回归”）的患者的频率、特征和结果尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究旨在调查急性心肌梗死 (AMI) 并接受高强度降脂治疗的患者三重回归的发生率、决定因素和预后影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：PACMAN-AMI 试验采用连续血管内超声、近红外光谱和光学相干断层扫描来比较 alirocumab 与安慰剂在接受高强度他汀类药物治疗的患者中的效果。三重回归是通过动脉粥样硬化百分比的组合存在来定义的体积 (PAV) 减少、最大脂质核心负荷指数 4 毫米以内 (maxLCBI <sub>4mm</sub> ) 减少、最小纤维帽厚度 (FCT) 增加。评估一年随访时的临床结果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：总体而言，84 名患者 (31.7%) 出现三重回归（alirocumab 组为 40.8%，安慰剂组为 23.0%，p=0.002）。无三重回归（组间差异 -27.1 [-37.7 至 -16.6] mg/dl，p&lt;0.001）。三重回归由 alirocumab 治疗独立预测（比值比 [OR] 2.83，95% 置信区间 [CI] 1.57-5.16，p=0.001）和更高的基线 maxLCBI <sub>4 mm</sub> （OR 1.03，95%CI 1.01-1.06，p=0.013）。与没有三重回归的情况相比（8.3% 与 18.2%，p=0.04）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：三分之一接受高强度降脂治疗的 AMI 患者出现三重回归，并且与 alirocumab 治疗、较高的基线脂质含量和减少的心血管事件相关。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37640248/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829060820&v=2.17.9.post6+86293ac">37640248</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.019>10.1016/j.jacc.2023.08.019</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37640248</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>弗拉维奥·G·比西雷</dc:creator><dc:creator>乔纳斯·汉纳</dc:creator><dc:creator>西尔万·洛斯达特</dc:creator><dc:creator>植木靖</dc:creator><dc:creator>涉谷弘树</dc:creator><dc:creator>大冢达彦</dc:creator><dc:creator>柿崎良太</dc:creator><dc:creator>托马斯·霍夫鲍尔</dc:creator><dc:creator>罗伯特·扬·范格恩斯</dc:creator><dc:creator>斯特凡·斯托特基</dc:creator><dc:creator>乔治斯·西昂蒂斯</dc:creator><dc:creator>莎拉·巴尔</dc:creator><dc:creator>雅各布·伦伯格</dc:creator><dc:creator>迪克·赫格</dc:creator><dc:creator>克里斯托夫·凯撒</dc:creator><dc:creator>大卫·斯皮克</dc:creator><dc:creator>乔斯特·戴门</dc:creator><dc:creator>胡安·伊格莱西亚斯</dc:creator><dc:creator>史蒂芬·温德克</dc:creator><dc:creator>托马斯·恩斯特罗姆</dc:creator><dc:creator>艾琳·朗</dc:creator><dc:creator>康斯坦丁诺斯·C·科斯基纳斯</dc:creator><dc:creator>洛伦兹·拉贝尔</dc:creator><dc:date>2023-08-28</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>降脂治疗后冠状动脉粥样硬化的消退和稳定</dc:title><dc:identifier>下午：37640248</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.019</dc:identifier></item><item><title>什么是正常左心室射血分数？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37639509/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829060820&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 29 日；148(9):750-752. doi: 10.1161/CIRCULATIONAHA.123.065791. Epub 2023 年 8 月 28 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639509/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829060820&v=2.17.9.post6+86293ac">37639509</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065791>10.1161 / CIRCULATIONAHA.123.065791</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639509</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>保罗·海登赖希</dc:creator><dc:date>2023-08-28</dc:date><dc:source>循环</dc:source><dc:title>什么是正常左心室射血分数？</dc:title><dc:identifier>下午：37639509</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065791</dc:identifier></item><item><title> Ostadal 和 Belohlavek 对有关文章“心源性休克治疗中的体外膜氧合：ECMO-CS 随机临床试验的结果”的信件的回应</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639508/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829060820&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 29 日；148(9):804.doi: 10.1161/CIRCULATIONAHA.123.065358. Epub 2023 年 8 月 28 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639508/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829060820&v=2.17.9.post6+86293ac">37639508</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065358>10.1161/CIRCULATIONAHA.123.065358</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639508</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>彼得·奥斯塔达尔更多</dc:creator><dc:creator>扬·贝洛拉维克</dc:creator><dc:date>2023-08-28</dc:date><dc:source>循环</dc:source><dc:title>Ostadal 和 Belohlavek 对有关文章“心源性休克治疗中的体外膜氧合：ECMO-CS 随机临床试验的结果”的信件的回应</dc:title><dc:identifier>下午：37639508</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065358</dc:identifier></item><item><title> Ferreira 关于文章“心源性休克治疗中的体外膜氧合：ECMO-CS 随机临床试验的结果”的信函</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639506/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829060820&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 29 日；148(9):803. doi: 10.1161/CIRCULATIONAHA.122.063622. Epub 2023 年 8 月 28 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639506/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829060820&v=2.17.9.post6+86293ac">37639506</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.063622>10.1161/CIRCULATIONAHA.122.063622</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639506</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>豪尔赫·费雷拉</dc:creator><dc:date>2023-08-28</dc:date><dc:source>循环</dc:source><dc:title>Ferreira 关于文章“心源性休克治疗中的体外膜氧合：ECMO-CS 随机临床试验的结果”的信函</dc:title><dc:identifier>下午：37639506</dc:identifier><dc:identifier> doi:10.1161/循环AHA.122.063622</dc:identifier></item><item><title>消除医学中结构性种族主义的阶段：关注医学培训</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639505/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829060820&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 29 日；148(9):800-802.doi: 10.1161/CIRCULATIONAHA.123.066131. ​​Epub 2023 年 8 月 28 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639505/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829060820&v=2.17.9.post6+86293ac">37639505</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066131>10.1161 / CIRCULATIONAHA.123.066131</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639505</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Nisha Donthi更多</dc:creator><dc:creator>凯瑟琳·R·露西</dc:creator><dc:creator>米歇尔·阿尔伯特</dc:creator><dc:date>2023-08-28</dc:date><dc:source>循环</dc:source><dc:title>消除医学中结构性种族主义的阶段：关注医学培训</dc:title><dc:identifier>下午：37639505</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066131</dc:identifier></item><item><title>高收入、中等收入和低收入国家心力衰竭患者的虚弱和结局</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639487/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829060820&amp;v=2.17.9.post6+86293ac<description>结论：虚弱为预测死亡和心衰住院的预后变量提供了大量增量预后信息。虚弱与这些结果之间的关系在所有收入水平的国家中都是一致的。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 28 日：ehad595。doi：10.1093/eurheartj/ehad595。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：除了来自不同国家收入水平的心力衰竭（HF）人群的传统预后变量之外，关于衰弱的增量预后重要性的信息很少。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：对来自 27 个高、中、低收入国家的 3429 名心力衰竭成人（年龄 61±14 岁，33% 女性）进行前瞻性研究。活动、意外体重减轻和自我报告的疲惫。平均左心室射血分数为 39±14%，26% 具有纽约心脏协会 (NYHA) III/IV 级症状。对参与者进行中位数（第 25-75 个百分位数）跟踪3.1（2.0-4.3）年。根据国家收入水平、年龄、性别、教育、使用、血压、血红蛋白、钠和肌酐浓度调整了死亡和心力衰竭住院的Cox比例风险模型。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在基线时，18% 的参与者身体健康，61% 的参与者处于虚弱状态，21% 的参与者虚弱。在随访期间，565 名参与者 (16%) 死亡，471 名参与者 (14%) 因心力衰竭住院。各自调整后的风险比 [衰弱前和衰弱者死亡的 HR (95% CI)] 分别为 1.59 (1.12-2.26) 和 2.92 (1.99-4.27)。1.33-2.91)。不同收入水平国家和大多数亚组的研究结果是一致的。 MAGGIC 风险评分改善了对未来死亡和心力衰竭住院治疗的区分。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：虚弱为预测死亡和心衰住院的预后变量提供了大量增量预后信息。虚弱与这些结果之间的关系在所有收入水平的国家中都是一致的。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639487/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829060820&v=2.17.9.post6+86293ac">37639487</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad595>10.1093/eurheartj/ehad595</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639487</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>达里尔·P·梁</dc:creator><dc:creator>菲利普·约瑟夫</dc:creator><dc:creator>约翰·JV·麦克默里</dc:creator><dc:creator>让·鲁洛</dc:creator><dc:creator>阿尔多·P·马吉奥尼</dc:creator><dc:creator>费尔南多·拉纳斯</dc:creator><dc:creator>桑吉布·K·夏尔马 (Sanjib K Sharma)</dc:creator><dc:creator>胡里奥·努涅斯</dc:creator><dc:creator>比沙夫·莫汉</dc:creator><dc:creator>艾哈迈德·塞利克</dc:creator><dc:creator>贾比尔·阿卜杜拉库蒂</dc:creator><dc:creator>奥克丘库·S·奥加</dc:creator><dc:creator>丽莎·米尔尼祖克</dc:creator><dc:creator>库马尔·巴拉苏布拉曼尼安</dc:creator><dc:creator>塔拉·麦克雷迪</dc:creator><dc:creator>——亚历克斯·格林瓦尔兹</dc:creator><dc:creator>萨利姆·优素福</dc:creator><dc:creator>P约瑟夫</dc:creator><dc:creator>G-CHF 研究人员</dc:creator><dc:date>2023-08-28</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>高收入、中等收入和低收入国家心力衰竭患者的虚弱和结局</dc:title><dc:identifier>下午：37639487</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad595</dc:identifier></item><item><title>第三代 PCSK9 抑制剂</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639486/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829060820&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 28 日：ehad566。doi：10.1093/eurheartj/ehad566。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639486/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829060820&v=2.17.9.post6+86293ac">37639486</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad566>10.1093/eurheartj/ehad566</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639486</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>乌尔里希·劳夫斯</dc:creator><dc:creator>马蒂亚斯·布吕赫</dc:creator><dc:creator>贝伦德·伊瑟曼</dc:creator><dc:date>2023-08-28</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>第三代 PCSK9 抑制剂</dc:title><dc:identifier>下午：37639486</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad566</dc:identifier></item><item><title> Emery-Dreifuss 型肌营养不良症 1 与恶性室性心律失常和终末期心力衰竭的高风险相关</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639473/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829060820&amp;v=2.17.9.post6+86293ac<description>结论：男性EMD变异携带者发生进行性心力衰竭和室性心律失常的风险与男性LMNA变异携带者相似，对于患有心脏病的男性EMD变异携带者应考虑早期植入式心脏复律除颤器植入和心力衰竭药物治疗。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 28 日：ehad561。doi：10.1093/eurheartj/ehad561。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：Emery-Dreifuss 肌营养不良症 (EDMD) 是由 EMD (EDMD1) 和 LMNA (EDMD2) 变异引起的。心脏传导缺陷和房性心律失常对两者都很常见，但 LMNA 变异也会导致终末期心力衰竭 (ESHF) ）和恶性室性心律失常（MVA）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：从 12 个国际心肌病病房回顾性招募连续转介的 EMD 变异携带者。确定男性和女性变异携带者的 MVA 和 ESHF 发生率。将基线时具有心脏表型 (EMDCARDIAC) 的男性 EMD 变异携带者与连续招募的患者进行比较基线时具有心脏表型的男性 LMNA 变异携带者 (LMNACARDIAC)。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：获得了 38 名男性和 21 名女性 EMD 变异携带者的纵向随访数据（平均 [SD] 年龄分别为 33.4 [13.3] 和 43.3 [16.8] 岁）。九名 (23.6%) 男性出现 MVA，五名 ( 13.2%）在中位 [IQR] 随访期间 [IQR] 65.0 [24.3, 109.5] 个月出现 ESHF。没有女性 EMD 变异携带者患有 MVA 或 ESHF，但 9 名 (42.8%) 在中位 [IQR] 时出现心脏表型年龄为 58.6 [53.2, 60.4] 岁。EMDCARDIAC 和 LMNACARDIAC 的 MVA 发病率相似（分别为每 100 人年 4.8 和 6.6；对数秩 p = 0.49）。ESHF 的发病率为每 100 人 2.4 和 5.9 EMDCARDIAC 和 LMNACARDIAC 分别为人年（对数秩 p = 0.09）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：男性EMD变异携带者发生进行性心力衰竭和室性心律失常的风险与男性LMNA变异携带者相似，对于患有心脏病的男性EMD变异携带者应考虑早期植入式心脏复律除颤器植入和心力衰竭药物治疗。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639473/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829060820&v=2.17.9.post6+86293ac">37639473</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad561>10.1093/eurheartj/ehad561</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639473</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>道格拉斯·E·坎尼</dc:creator><dc:creator>彼得罗斯·西里斯</dc:creator><dc:creator>亚历山德罗斯·普罗托塔里奥斯</dc:creator><dc:creator>阿塔纳西奥斯·巴卡拉科斯</dc:creator><dc:creator>让-弗朗索瓦·普鲁尼</dc:creator><dc:creator>拉斐尔·迪塔兰托</dc:creator><dc:creator>克里斯蒂娜·马丁内斯·维拉</dc:creator><dc:creator>何塞·M·拉拉纳加-莫雷拉</dc:creator><dc:creator>克里斯汀·梅多</dc:creator><dc:creator>弗朗西斯科·何塞·贝穆德斯-希门尼斯</dc:creator><dc:creator>拉巴·本·亚乌</dc:creator><dc:creator>法国勒图尔克</dc:creator><dc:creator>艾尼霍亚·罗伯斯·梅斯库亚</dc:creator><dc:creator>基亚拉·马里尼·贝托洛</dc:creator><dc:creator>伊娃·卡布雷拉</dc:creator><dc:creator>克洛伊路透社</dc:creator><dc:creator>哈维尔·利梅雷斯·弗莱雷</dc:creator><dc:creator>何塞·F·罗德里格斯-帕洛马雷斯</dc:creator><dc:creator>路易莎·梅斯特罗尼</dc:creator><dc:creator>——马修·R·G·泰勒</dc:creator><dc:creator>维多利亚·N·帕里克</dc:creator><dc:creator>尤安·阿什利</dc:creator><dc:creator>罗伯托·巴里亚莱斯-维拉</dc:creator><dc:creator>胡安·希门尼斯·雅梅斯</dc:creator><dc:creator>巴勃罗·加西亚-帕维亚</dc:creator><dc:creator>菲利普·查伦</dc:creator><dc:creator>埃琳娜·比亚吉尼</dc:creator><dc:creator>何塞·M·加西亚·皮尼利亚</dc:creator><dc:creator>约翰·伯克</dc:creator><dc:creator>康斯坦丁诺斯·萨瓦蒂斯</dc:creator><dc:creator>卡里姆·瓦赫比</dc:creator><dc:creator>佩里·埃利奥特</dc:creator><dc:date>2023-08-28</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>Emery-Dreifuss 型肌营养不良症 1 与恶性室性心律失常和终末期心力衰竭的高风险相关</dc:title><dc:identifier>下午：37639473</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad561</dc:identifier></item><item><title>虚弱：心力衰竭的新生命体征成熟</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639470/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829060820&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 28 日：ehad559。doi：10.1093/eurheartj/ehad559。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639470/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829060820&v=2.17.9.post6+86293ac">37639470</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad559>10.1093/eurheartj/ehad559</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639470</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>芬利·麦卡利斯特</dc:creator><dc:date>2023-08-28</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>虚弱：心力衰竭的新生命体征成熟</dc:title><dc:identifier>下午：37639470</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad559</dc:identifier></item><item><title> lerodalcibep 对杂合子家族性高胆固醇血症的长期疗效和安全性：LIBERate-HeFH 试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639462/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829060820&amp;v=2.17.9.post6+86293ac<description>结论：Lerodalcibep 是一种新型抗 PCSK9 小结合蛋白，每月给药一次，作为单克隆抗体的替代品，可显着降低 HeFH 受试者的 LDL-C，且安全性与安慰剂相似。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 28 日：ehad596。doi：10.1093/eurheartj/ehad596。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目标：Lerodalcibep 是一种由 PCSK9 结合域（adnectin）和人血清白蛋白组成的新型小型重组融合蛋白，每月 300 mg 1.2 ml SC 剂量阶段性证明可高效降低低密度脂蛋白胆固醇（LDL-C） 2. 在这项全球 3 期试验中，在需要额外降低 LDL-C 的杂合子家族性高胆固醇血症 (HeFH) 患者中评估了 lerodalcibep 的安全性和有效性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：患者以 2:1 的比例随机分组，每月皮下注射 lerodalcibep 300 mg 或安慰剂，持续 24 周。主要疗效终点是第 24 周时 LDL-C 相对于基线的百分比变化以及第 22 周和第 24 周的平均值。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 478 名随机受试者中[平均年龄（范围）；53 (18-80) 岁，51.7% 女性，平均 (SD) 基线 LDL-C 3.88 (1.66) mmol/L] 与安慰剂相比，lerodalcibep 降低了 LDL-C绝对量为 2.08 (0.11) mmol/L [LS 平均值 (SE)；95% CI -2.30 至 -1.87]，第 24 周时的百分比差异为 -58.61 (3.25)%，增加 2.28 (0.10) mmol/ L L (95% CI -2.47 至 -2.09)，第 22 周和第 24 周的平均值百分比差异为 -65.0 (2.87)%（所有 P &lt; 0.0001）。使用 lerodalcibep，68% 的受试者实现了降低研究期间 LDL-C ≥ 50% 和推荐的 ESC LDL-C 目标。除了轻微的注射部位反应外，lerodalcibep 和安慰剂之间治疗引起的不良事件相似。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：Lerodalcibep 是一种新型抗 PCSK9 小结合蛋白，每月给药一次，作为单克隆抗体的替代品，可显着降低 HeFH 受试者的 LDL-C，且安全性与安慰剂相似。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639462/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829060820&v=2.17.9.post6+86293ac">37639462</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad596>10.1093/eurheartj/ehad596</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639462</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>弗雷德里克·拉尔</dc:creator><dc:creator>尼达·福里</dc:creator><dc:creator>拉塞尔·斯科特</dc:creator><dc:creator>德克·布洛姆</dc:creator><dc:creator>马蒂斯·德弗里斯·巴松</dc:creator><dc:creator>梅拉尔·卡伊克吉奥卢</dc:creator><dc:creator>——凯特·考德威尔</dc:creator><dc:creator>大卫·卡伦德</dc:creator><dc:creator>埃文·斯坦因</dc:creator><dc:creator>LIBerate-HeFH 调查人员</dc:creator><dc:date>2023-08-28</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>lerodalcibep 对杂合子家族性高胆固醇血症的长期疗效和安全性：LIBERate-HeFH 试验</dc:title><dc:identifier>下午：37639462</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad596</dc:identifier></item><item><title> Mavacamten 对有症状的梗阻性肥厚型心肌病患者的长期疗效和安全性</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639276/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829060820&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 8 月 28 日。doi：10.1001/jamacardio.2023.3357。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639276/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829060820&v=2.17.9.post6+86293ac">37639276</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3357>10.1001/jamacardio.2023.3357</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639276</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>莎琳·M·戴</dc:creator><dc:creator>——詹姆斯·E·乌德尔森</dc:creator><dc:creator>罗伯特·奥博诺</dc:creator><dc:date>2023-08-28</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>Mavacamten 对有症状的梗阻性肥厚型心肌病患者的长期疗效和安全性</dc:title><dc:identifier>下午：37639276</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3357</dc:identifier></item><item><title> Mavacamten 在中国治疗梗阻性肥厚型心肌病</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639265/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829060820&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 8 月 28 日。doi：10.1001/jamacardio.2023.3045。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639265/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829060820&v=2.17.9.post6+86293ac">37639265</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3045>10.1001/jamacardio.2023.3045</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639265</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>米林德·德赛</dc:creator><dc:date>2023-08-28</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>Mavacamten 在中国治疗梗阻性肥厚型心肌病</dc:title><dc:identifier>下午：37639265</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3045</dc:identifier></item><item><title> Mavacamten 对中国症状性梗阻性肥厚型心肌病患者的影响：EXPLORER-CN 随机临床试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639259/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829060820&amp;v=2.17.9.post6+86293ac<description>结论：与安慰剂相比，Mavacamten 显着改善了中国患者的 Valsalva LVOT 梯度。所有次要疗效终点也得到改善。Mavacamten 耐受性良好，没有新的安全信号。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 8 月 28 日。doi：10.1001/jamacardio.2023.3030。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：Mavacamten 在全球研究中显示出对梗阻性肥厚型心肌病 (oHCM) 患者的临床益处，但缺乏亚洲人群的证据。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：评估 mavacamten 与安慰剂相比对中国有症状 oHCM 患者的安全性和有效性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、环境和受试者：这项 3 期、随机、双盲、安慰剂对照临床试验在中国 12 家医院进行。2022 年 1 月 4 日至 8 月 5 日期间，患有 oHCM 和左心室流出道（LVOT）的患者) 梯度为 50 mm Hg 或以上且纽约心脏协会 (NYHA) II 级或 III 级症状被纳入并接受 30 周的治疗。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">干预措施：患者按照 2:1 的比例随机接受 mavacamten（从 2.5 mg 每天一次开始）或安慰剂治疗，持续 30 周。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结局和测量：主要终点是 Valsalva LVOT 峰值梯度从基线到第 30 周的变化。通过超声心动图评估左心室流出道梯度和左心室射血分数 (LVEF)，同时确定左心室质量指数 (LVMI)通过心脏磁共振成像进行分析。分析是在意向治疗的基础上进行的。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：共有 81 名患者（平均 [SD] 年龄，51.9 [11.9] 岁；58 名男性 [71.6%]）被随机分组​​。与安慰剂相比，Mavacamten 在主要终点方面有显着改善（最小二乘均值 [LSM] ] 差异，-70.3 mm Hg；95% CI，-89.6 至 -50.9 mm Hg；单侧 P &lt; .001）。静息 LVOT 峰值梯度也表现出类似的趋势（LSM 差异，-55.0 mm Hg；95% CI ，-69.1 至 -40.9 mm Hg）。在第 30 周时，与安慰剂相比，更多接受 mavacamten 的患者达到低于 30 mm Hg 的 Valsalva LVOT 峰值梯度（48.1% [54 人中的 26 人] vs 3.7% [27 人中的 1 人]），更少低于 50 mm Hg（59.3% [54 中的 32] vs 7.4% [27 中的 2]），以及 NYHA 等级改善（59.3% [54 中的 32] vs 14.8% [27 中的 4]）。mavacamten 关于堪萨斯城心肌病问卷临床总结评分（LSM差值，10.2；95% CI，4.4-16.1），N末端B型利钠肽原水平（几何平均比的比例，0.18；95% CI，0.13）-0.24），高-敏感性心肌肌钙蛋白 I 水平（几何平均比比例，0.34；95% CI，0.27-0.42）和 LVMI（平均差，-30.8 g/m2；95% CI，-41.6 至 -20.1）g/m2） . mavacamten 和安慰剂的安全性和耐受性相似。没有患者的 LVEF 低于 50%。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：与安慰剂相比，Mavacamten 显着改善了中国患者的 Valsalva LVOT 梯度。所有次要疗效终点也得到改善。Mavacamten 耐受性良好，没有新的安全信号。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">试验注册：ClinicalTrials.gov 标识符：NCT05174416。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639259/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829060820&v=2.17.9.post6+86293ac">37639259</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3030>10.1001/jamacardio.2023.3030</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639259</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>庄田</dc:creator><dc:creator>李丽文</dc:creator><dc:creator>李晓燕</dc:creator><dc:creator>王建安</dc:creator><dc:creator>张庆</dc:creator><dc:creator>李占全</dc:creator><dc:creator>彭道全</dc:creator><dc:creator>平阳</dc:creator><dc:creator>维玛</dc:creator><dc:creator>王芳</dc:creator><dc:creator>魏晋</dc:creator><dc:creator>向成</dc:creator><dc:creator>孙晶</dc:creator><dc:creator>付逸群</dc:creator><dc:creator>程吕</dc:creator><dc:creator>张书阳</dc:creator><dc:date>2023-08-28</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>Mavacamten 对中国症状性梗阻性肥厚型心肌病患者的影响：EXPLORER-CN 随机临床试验</dc:title><dc:identifier>下午：37639259</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3030</dc:identifier></item><item><title> Mavacamten 治疗肥厚型心肌病转诊进行室间隔复位术的患者：VALOR-HCM 随机临床试验第 56 周结果</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639243/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829060820&amp;v=2.17.9.post6+86293ac<description>结论和相关性：这项随机临床试验的结果表明，在有症状的梗阻性 HCM 患者中，mavacamten 减少了第 56 周时对 SRT 的需求，并持续改善 LVOT 梯度和症状。监控。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 8 月 28 日。doi：10.1001/jamacardio.2023.3342。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：在为患有严重症状的梗阻性肥厚型心肌病 (HCM) 患者推荐侵入性治疗之前，对新的药物治疗的需求尚未得到满足。Mavacamten 已被证明可以改善左心室流出道 (LVOT) 梯度和症状，从而可能减少短时间收缩。短期需要间隔缩小治疗（SRT）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：检查 mavacamten 对 SRT 需求至第 56 周的累积长期影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、环境和参与者：这是一项双盲、安慰剂对照、多中心、随机临床试验，为期 16 周，安慰剂交叉，于 2020 年 7 月至 2022 年 11 月进行。参与者来自 19 个美国 HCM 中心。试验为患者患有阻塞性 HCM（纽约心脏协会 III/IV 级）转诊接受 SRT。研究数据于 2023 年 4 月至 8 月进行分析。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">干预措施：最初在基线时分配到 mavacamten 的患者继续用药 56 周，服用安慰剂的患者从第 16 周到第 56 周（暴露 40 周）交叉到 mavacamten。使用超声心动图 LVOT 梯度和 LV 射血分数进行剂量滴定（左心室射血分数 (LVEF) 测量。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和测量：第 56 周时接受 SRT、仍符合指南要求或无法评估 SRT 状态的患者比例。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 112 名症状严重的梗阻性 HCM 患者中，108 名（平均 [SD] 年龄，60.3 [12.5] 岁；54 名男性 [50.0%]）符合第 56 周评估的条件。在第 56 周，56 名患者中有 5 名（8.9%） ））在原始 mavacamten 组中（3 例接受了 SRT，1 例符合 SRT 条件，1 例不可评估 SRT）和安慰剂交叉组 52 名患者中的 10 例（19.2%）（3 例接受了 SRT，4 例符合 SRT 条件，3 例接受了 SRT） 108 名患者中，共有 96 名患者 (89%) 长期继续使用 mavacamten。56 周后，mavacamten 组和安慰剂-mavacamten 组之间，静息持续减少（平均差为 -34.0 mm Hg； 95% CI，-43.5 至 -24.5 mm Hg 和 -33.2 mm Hg；95% CI，-41.9 至 -24.5 mm Hg）和 Valsalva（平均差，-45.6 mm Hg；95% CI，-56.5 至 -34.6 mm Hg 和 -54.6 mm Hg；95% CI，-66.0 至 -43.3 mm Hg) LVOT 梯度。总体而言，108 名患者中有 12 名（11.1%；95% CI，5.87%–18.60%），即 56 名患者中的 7 名。原始 mavacamten 组中的 5 名 (12.5%) 和安慰剂交叉组中 52 名患者中的 5 名 (9.6%) 的 LVEF 低于 50%（2 名 LVEF ≤ 30%，其中 1 名死亡），以及 12 名患者中的 9 名(75%) 继续治疗。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：这项随机临床试验的结果表明，在有症状的梗阻性 HCM 患者中，mavacamten 减少了第 56 周时对 SRT 的需求，并持续改善 LVOT 梯度和症状。监控。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">试验注册：ClinicalTrials.gov 标识符：NCT04349072。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639243/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829060820&v=2.17.9.post6+86293ac">37639243</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3342>10.1001/jamacardio.2023.3342</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639243</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>米林德·德赛</dc:creator><dc:creator>安贾利·欧文斯</dc:creator><dc:creator>凯西·沃尔斯基</dc:creator><dc:creator>杰弗里·B·盖斯克</dc:creator><dc:creator>萨拉·萨贝里</dc:creator><dc:creator>安德鲁·王</dc:creator><dc:creator>——马克·谢里德</dc:creator><dc:creator>保罗·C·克莱默</dc:creator><dc:creator>Neal K Lakdawala更多</dc:creator><dc:creator>阿尔伯里·塔尔-雷德</dc:creator><dc:creator>大卫·费明</dc:creator><dc:creator>Srihari S Naidu更多</dc:creator><dc:creator>尼古拉斯·G·斯梅德拉</dc:creator><dc:creator>哈泽尔·沙夫</dc:creator><dc:creator>埃伦·麦克尔林</dc:creator><dc:creator>克里斯蒂娜·休厄尔</dc:creator><dc:creator>拉娜·穆达里斯</dc:creator><dc:creator>宫志群</dc:creator><dc:creator>凯西·兰普尔</dc:creator><dc:creator>艾米·J·塞纳特</dc:creator><dc:creator>史蒂文·E·尼森</dc:creator><dc:date>2023-08-28</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>Mavacamten 治疗肥厚型心肌病转诊进行室间隔复位术的患者：VALOR-HCM 随机临床试验第 56 周结果</dc:title><dc:identifier>下午：37639243</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3342</dc:identifier></item><item><title>心房颤动舒张功能障碍的患病率和发生率：临床意义</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639219/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829060820&amp;v=2.17.9.post6+86293ac<description>结论：新发 AF 患者在诊断时表现出 HFpEF 的高风险特征，强调了在有症状的 AF 患者中评估 HFpEF 的重要性。随着时间的推移，新发 AF 患者的 DD 进展加速，这可能会识别出患有以下疾病的患者：临床前 HFpEF，可以测试预防性治疗。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 28 日：ehad592。doi：10.1093/eurheartj/ehad592。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：心房颤动 (AF) 和射血分数保留的心力衰竭 (HFpEF) 是密切相关的疾病。当症状仅归因于心律失常时，AF 中的 HFpEF 可能会被忽视，而意外发生的 AF 可能会识别出有发生舒张功能障碍风险的患者。 (DD).本研究旨在调查与窦性心律 (SR) 相比，新发 AF 患者 DD 的患病率和发生率。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：确定患有新发 AF（n = 1,747）或 SR（n = 29,623）且无结构性心脏病的成年人。根据年龄、性别、重度 DD (SDD) 定义为 ≥3/4 异常参数（内侧 e&#39;、内侧 E/e&#39;、三尖瓣反流速度、左心房容积指数），≥中度 (MDD) ≥2 /4.确定了DD指数的年化变化。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：新发 AF 与 SDD（8% vs 3%）和≥MDD（25% vs 16%）独立相关。62% 的 AF 患者具有高危 H2FPEF 评分，5% 具有临床公认的 HFpEF。在中位随访 3.2 年（四分位距 1.6-5.8）年中，新发 AF 患者的 DD 进展速度快了 2-4 倍（所有患者均 p &lt; 0.001）。发生 DD 的风险在新发 AF 患者中增加。发病 AF [SDD 的风险比（95% 置信区间）为 2.69 (2.19-3.32)，≥MDD 的风险比为 1.73 (1.49-2.02)]。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：新发 AF 患者在诊断时表现出 HFpEF 的高风险特征，强调了在有症状的 AF 患者中评估 HFpEF 的重要性。随着时间的推移，新发 AF 患者的 DD 进展加速，这可能会识别出患有以下疾病的患者：临床前 HFpEF，可以测试预防性疗法。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639219/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829060820&v=2.17.9.post6+86293ac">37639219</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad592>10.1093/eurheartj/ehad592</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639219</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>贾万·纳赛尔</dc:creator><dc:creator>李恩静</dc:creator><dc:creator>克里斯托弗·斯科特</dc:creator><dc:creator>奥斯汀·M·肯尼迪</dc:creator><dc:creator>帕特里夏·佩利卡</dc:creator><dc:creator>——格蕾丝·林</dc:creator><dc:creator>索林·V·皮斯拉鲁</dc:creator><dc:creator>巴里·博洛格</dc:creator><dc:date>2023-08-28</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>心房颤动舒张功能障碍的患病率和发生率：临床意义</dc:title><dc:identifier>下午：37639219</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad592</dc:identifier></item><item><title>窦房结功能障碍中的心房起搏和心房颤动：仍然难以捉摸的关系</title><link/>https://pubmed.ncbi.nlm.nih.gov/37638993/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829060820&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 28 日：ehad569。doi：10.1093/eurheartj/ehad569。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37638993/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829060820&v=2.17.9.post6+86293ac">37638993</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad569>10.1093/eurheartj/ehad569</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37638993</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>拉蒂卡·帕卡什</dc:creator><dc:date>2023-08-28</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>窦房结功能障碍中的心房起搏和心房颤动：仍然难以捉摸的关系</dc:title><dc:identifier>下午：37638993</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad569</dc:identifier></item><item><title> Atrial pacing minimization in sinus node dysfunction and risk of incident atrial fibrillation: a randomized trial</title><link/> https://pubmed.ncbi.nlm.nih.gov/37638973/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829060820&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Atrial pacing minimization in patients with sinus node dysfunction does not reduce the incidence of atrial fibrillation. Programming a base rate of 40 bpm without rate-adaptive pacing is associated with an increased risk of syncope or presyncope. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 28:ehad564. doi: 10.1093/eurheartj/ehad564. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: High percentages of atrial pacing have been associated with an increased risk of atrial fibrillation. This study aimed at evaluating whether atrial pacing minimization in patients with sinus node dysfunction reduces the incidence of atrial fibrillation. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: In a nationwide, randomized controlled trial, 540 patients with sinus node dysfunction and an indication for first pacemaker implantation were assigned to pacing programmed to a base rate of 60 bpm and rate-adaptive pacing (DDDR-60) or pacing programmed to a base rate of 40 bpm without rate-adaptive pacing (DDD-40). Patients were followed on remote monitoring for 2 years. The primary endpoint was time to first episode of atrial fibrillation longer than 6 min. Secondary endpoints included longer episodes of atrial fibrillation, and the safety endpoint comprised a composite of syncope or presyncope. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: The median percentage of atrial pacing was 1% in patients assigned to DDD-40 and 49% in patients assigned to DDDR-60. The primary endpoint occurred in 124 patients (46%) in each treatment group (hazard ratio [HR] 0.97, 95% confidence interval [CI] 0.76-1.25, P=0.83). There were no between-group differences in atrial fibrillation exceeding 6- or 24 hours, persistent atrial fibrillation, or cardioversions for atrial fibrillation. The incidence of syncope or presyncope was higher in patients assigned to DDD-40 (HR 1.71 95% CI 1.13-2.59, P=0.01). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Atrial pacing minimization in patients with sinus node dysfunction does not reduce the incidence of atrial fibrillation. Programming a base rate of 40 bpm without rate-adaptive pacing is associated with an increased risk of syncope or presyncope.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37638973/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829060820&v=2.17.9.post6+86293ac">37638973</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad564>10.1093/eurheartj/ehad564</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37638973</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Mads Brix Kronborg</dc:creator><dc:creator> Maria Hee Jung Park Frausing</dc:creator><dc:creator> Jerzy Malczynski</dc:creator><dc:creator> Sam Riahi</dc:creator><dc:creator> Jens Haarbo</dc:creator><dc:creator> Katja Fiedler Holm</dc:creator><dc:creator> Charlotte Ellen Larroudé</dc:creator><dc:creator> Andi Eie Albertsen</dc:creator><dc:creator> Lene Svendstrup</dc:creator><dc:creator> Ulrik Hintze</dc:creator><dc:creator> Ole Dyg Pedersen</dc:creator><dc:creator> Ulla Davidsen</dc:creator><dc:creator> Thomas Fischer</dc:creator><dc:creator> Jens Brock Johansen</dc:creator><dc:creator> Jens Kristensen</dc:creator><dc:creator> Christian Gerdes</dc:creator><dc:creator> Jens Cosedis Nielsen</dc:creator><dc:creator> DANPACE II Investigators</dc:creator><dc:date> 2023-08-28</dc:date><dc:source> European heart journal</dc:source><dc:title> Atrial pacing minimization in sinus node dysfunction and risk of incident atrial fibrillation: a randomized trial</dc:title><dc:identifier> pmid:37638973</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad564</dc:identifier></item><item><title> Edoxaban for 12 Months Versus 3 Months in Cancer Patients With Isolated Distal Deep Vein Thrombosis (ONCO DVT study): An Open-label, Multicenter, Randomized Clinical Trial</title><link/> https://pubmed.ncbi.nlm.nih.gov/37638968/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829060820&amp;v=2.17.9.post6+86293ac<description> Background: The optimal duration of anticoagulation therapy for isolated distal deep vein thrombosis (DVT) in patients with cancer is clinically relevant, but the evidence is lacking. The prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events, however, it could also increase the risk of bleeding. Methods: In a multicenter, open-label, adjudicator-blinded, randomized clinical trial at 60 institutions in Japan, we randomly assigned cancer patients with... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Aug 28. doi: 10.1161/CIRCULATIONAHA.123.066360. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> <b>Background:</b> The optimal duration of anticoagulation therapy for isolated distal deep vein thrombosis (DVT) in patients with cancer is clinically relevant, but the evidence is lacking. The prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events, however, it could also increase the risk of bleeding. <b>Methods:</b> In a multicenter, open-label, adjudicator-blinded, randomized clinical trial at 60 institutions in Japan, we randomly assigned cancer patients with isolated distal DVT, in a 1-to-1 ratio, to receive either a 12-month or 3-month edoxaban treatment. The primary endpoint was a composite of a symptomatic recurrent venous thromboembolism (VTE) or VTE-related death at 12 months. The major secondary endpoint was major bleeding at 12 months, according to the criteria of the International Society on Thrombosis and Hemostasis. The primary hypothesis was that a 12-month edoxaban treatment was superior to a 3-month edoxaban treatment with respect to the primary endpoint. <b>Results:</b> From April 2019 through June 2022, 604 patients were randomized, and after excluding 3 patients who withdrew consent, 601 patients were included in the intention-to-treat population: 296 patients in the 12-month edoxaban group and 305 patients in the 3-month edoxaban group. The mean age was 70.8 years, 28% of the patients were men, and 20% of the patients had symptoms of DVT at baseline. The primary endpoint of a symptomatic recurrent VTE event or VTE-related death occurred in 3 of the 296 patients (1.0%) in the 12-month edoxaban group and in 22 of the 305 (7.2%) in the 3-month edoxaban group (odds ratio, 0.13; 95% CI, 0.03 to 0.44). The major secondary endpoint of major bleeding occurred in 28 of the 296 patients (9.5%) in the 12-month edoxaban group and in 22 of the 305 (7.2%) in the 3-month edoxaban group (odds ratio, 1.34; 95% CI, 0.75 to 2.41). The prespecified subgroups did not affect the estimates on the primary endpoint. <b>Conclusions:</b> In cancer patients with isolated distal DVT, 12 months was superior to 3 months for an edoxaban treatment with respect to the composite outcome of a symptomatic recurrent VTE or VTE-related death.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37638968/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829060820&v=2.17.9.post6+86293ac">37638968</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066360>10.1161/CIRCULATIONAHA.123.066360</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37638968</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Yugo Yamashita</dc:creator><dc:creator> Takeshi Morimoto</dc:creator><dc:creator> Nao Muraoka</dc:creator><dc:creator> Takuya Oyakawa</dc:creator><dc:creator> Michihisa Umetsu</dc:creator><dc:creator> Daijirou Akamatsu</dc:creator><dc:creator> Yuji Nishimoto</dc:creator><dc:creator> Yukihito Sato</dc:creator><dc:creator> Takuma Takada</dc:creator><dc:creator> Kentaro Jujo</dc:creator><dc:creator> Yuichiro Minami</dc:creator><dc:creator> Yoshito Ogihara</dc:creator><dc:creator> Kaoru Dohi</dc:creator><dc:creator> Masashi Fujita</dc:creator><dc:creator> Tatsuya Nishikawa</dc:creator><dc:creator> Nobutaka Ikeda</dc:creator><dc:creator> Go Hashimoto</dc:creator><dc:creator> Kazunori Otsui</dc:creator><dc:creator> Kenta Mori</dc:creator><dc:creator> Daisuke Sueta</dc:creator><dc:creator> Yukari Tsubata</dc:creator><dc:creator> Masaaki Shoji</dc:creator><dc:creator> Ayumi Shikama</dc:creator><dc:creator> Yutaka Hosoi</dc:creator><dc:creator> Yasuhiro Tanabe</dc:creator><dc:creator> Ryuki Chatani</dc:creator><dc:creator> Kengo Tsukahara</dc:creator><dc:creator> Naohiko Nakanishi</dc:creator><dc:creator> Kitae Kim</dc:creator><dc:creator> Satoshi Ikeda</dc:creator><dc:creator> Makoto Mo</dc:creator><dc:creator> Yusuke Yoshikawa</dc:creator><dc:creator> Takeshi Kimura</dc:creator><dc:creator> ONCO DVT Study Investigators</dc:creator><dc:date> 2023-08-28</dc:date><dc:source> Circulation</dc:source><dc:title> Edoxaban for 12 Months Versus 3 Months in Cancer Patients With Isolated Distal Deep Vein Thrombosis (ONCO DVT study): An Open-label, Multicenter, Randomized Clinical Trial</dc:title><dc:identifier> pmid:37638968</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.066360</dc:identifier></item><item><title> Quality and transparency of evidence for implantable cardiovascular medical devices assessed by the CORE-MD Consortium</title><link/> https://pubmed.ncbi.nlm.nih.gov/37638967/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829060820&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: The quantity and quality of publicly available data from prospective clinical investigations across selected categories of cardiovascular devices, before and after CE approval during the period 2000-2021, was deemed insufficient. The majority of studies were non-randomized, with increased risk of bias, and performed in small populations without provision of power calculations, and none of the reviewed devices had randomized trial results published prior to CE mark certification. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 28:ehad567. doi: 10.1093/eurheartj/ehad567. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: The European Union Medical Device Regulation 2017/745 challenges key stakeholders to follow transparent and rigorous approaches to the clinical evaluation of medical devices. The purpose of this study is a systematic evaluation of published clinical evidence underlying selected high-risk cardiovascular medical devices before and after market access in the European Union (CE marking) between 2000 and 2021. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Prespecified strategies were applied to identify published studies of prospective design evaluating 71 high-risk cardiovascular devices in 7 different classes (bioresorbable coronary scaffolds, left atrial appendage occlusion devices, transcatheter aortic valve implantation systems, transcatheter mitral valve repair/replacement systems, surgical aortic and mitral heart valves, leadless pacemakers, subcutaneous implantable cardioverter-defibrillator). The search time-span covered 20 years (2000-2021). Details of study design, patient population, intervention(s) and primary outcome(s) were summarized, and assessed with respect to timing of the corresponding CE-mark approval. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: At least one prospective clinical trial was identified for 70% (50/71) of the prespecifed devices. Overall, 473 reports of 308 prospectively designed studies (enrolling 97,886 individuals) were deemed eligible, including 81% (251/308) prospective non-randomized clinical trials (66,186 individuals) and 19% (57/308) randomized clinical trials (31,700 individuals). Preregistration of the study protocol was available in 49% (150/308) studies, and 16% (48/308) had a peer-reviewed publicly available protocol. Device-related adverse events were evaluated in 82% (253/308) of studies. An outcome adjudication process was reported in 39% (120/308) of the studies. Sample size was larger for randomized in comparison to non-randomized trials (median of 304 versus 100 individuals, p&lt;0.001). No randomized clinical trial published before CE-mark approval for any of the devices was identified. Non-randomized clinical trials were predominantly published after the corresponding CE-mark approval of the device under evaluation (89%, 224/251). Sample sizes were smaller for studies published before (median of 34 individuals) than after (median of 135 individuals) CE-mark approval (p&lt;0.001). Clinical trials with larger sample sizes (>;50 individuals) and those with longer recruitment periods were more likely to be published after CE-mark approval, and were more frequent during the period 2016-2021. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: The quantity and quality of publicly available data from prospective clinical investigations across selected categories of cardiovascular devices, before and after CE approval during the period 2000-2021, was deemed insufficient. The majority of studies were non-randomized, with increased risk of bias, and performed in small populations without provision of power calculations, and none of the reviewed devices had randomized trial results published prior to CE mark certification.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37638967/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829060820&v=2.17.9.post6+86293ac">37638967</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad567>10.1093/eurheartj/ehad567</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37638967</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> George Cm Siontis</dc:creator><dc:creator> Bernadette Coles</dc:creator><dc:creator> Jonas D Häner</dc:creator><dc:creator> Laurna McGovern</dc:creator><dc:creator> Joanna Bartkowiak</dc:creator><dc:creator> JJ Coughlan</dc:creator><dc:creator> Alessandro Spirito</dc:creator><dc:creator> Roberto Galea</dc:creator><dc:creator> Andreas Haeberlin</dc:creator><dc:creator> Fabien Praz</dc:creator><dc:creator> Daijiro Tomii</dc:creator><dc:creator> Tom Melvin</dc:creator><dc:creator> André Frenk</dc:creator><dc:creator> Robert A Byrne</dc:creator><dc:creator> Alan G Fraser</dc:creator><dc:creator> Stephan Windecker</dc:creator><dc:creator> CORE-MD investigators</dc:creator><dc:date> 2023-08-28</dc:date><dc:source> European heart journal</dc:source><dc:title> Quality and transparency of evidence for implantable cardiovascular medical devices assessed by the CORE-MD Consortium</dc:title><dc:identifier> pmid:37638967</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad567</dc:identifier></item><item><title> Type A aortic dissection: optimal annual case volume for surgery</title><link/> https://pubmed.ncbi.nlm.nih.gov/37638786/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829060820&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Using this novel approach, the optimal hospital case volume threshold was statistically determined. Centralization of ATAAD care to high-volume centres may lead to improved outcomes. This method can be applied to various other cardiovascular procedures requiring centralization. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 28:ehad551. doi: 10.1093/eurheartj/ehad551. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: The current study proposes a novel volume-outcome (VO) meta-analytical approach to determine the optimal annual hospital case volume threshold for cardiovascular interventions in need of centralization. This novel method is applied to surgery for acute type A aortic dissection (ATAAD) as an illustrative example. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: A systematic search was applied to three electronic databases (January 1st 2012 - March 29th 2023). The primary outcome was early mortality in relation to annual hospital case volume. Data were presented by volume quartiles (Qs). Restricted cubic splines were used to demonstrate the VO relation, and the elbow method was applied to determine the optimal case volume. For clinical interpretation, numbers needed to treat (NNT) were calculated. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: 140 studies were included, comprising 38276 patients. A significant non-linear VO effect was observed (p&lt;0.001), with a significant between-quartile difference for early mortality (10.3% [Q4] vs. 16.2% [Q1], p&lt;0.001). The optimal annual case volume was determined at 38 cases/year (95% CI 37-40 cases/year, NNT to save a life in a centre with the optimal volume vs. 10 cases/year = 21). More pronounced between-quartile survival differences were observed for long-term survival (10-year survival [Q4] 69% vs. [Q1] 51%, p&lt;0.001, adjusted HR 0.83, 95% CI 0.75-0.91 per quartile, NNT to save a life in a high-volume [Q4] vs. low-volume centre [Q1) = 6). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Using this novel approach, the optimal hospital case volume threshold was statistically determined. Centralization of ATAAD care to high-volume centres may lead to improved outcomes. This method can be applied to various other cardiovascular procedures requiring centralization.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37638786/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829060820&v=2.17.9.post6+86293ac">37638786</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad551>10.1093/eurheartj/ehad551</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37638786</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Michael J Kawczynski</dc:creator><dc:creator> Sander MJ van Kuijk</dc:creator><dc:creator> Jules R Olsthoorn</dc:creator><dc:creator> Jos G Maessen</dc:creator><dc:creator> Suzanne Kats</dc:creator><dc:creator> Elham Bidar</dc:creator><dc:creator> Samuel Heuts</dc:creator><dc:date> 2023-08-28</dc:date><dc:source> European heart journal</dc:source><dc:title> Type A aortic dissection: optimal annual case volume for surgery</dc:title><dc:identifier> pmid:37638786</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad551</dc:identifier></item><item><title> Acute type A aortic dissection: stay and play or load and run?</title><link/> https://pubmed.ncbi.nlm.nih.gov/37638778/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829060820&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 28:ehad517. doi: 10.1093/eurheartj/ehad517. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37638778/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829060820&v=2.17.9.post6+86293ac">37638778</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad517>10.1093/eurheartj/ehad517</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37638778</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Tim Berger</dc:creator><dc:creator> Maximilian Kreibich</dc:creator><dc:creator> Martin Czerny</dc:creator><dc:date> 2023-08-28</dc:date><dc:source> European heart journal</dc:source><dc:title> Acute type A aortic dissection: stay and play or load and run?</dc:title><dc:identifier> pmid:37638778</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad517</dc:identifier></item></channel></rss>